Prognosis
FDA Advisers Back Authorization of Moderna’s Covid Vaccine
- Advisory committee votes that shot’s benefit outweigh risks
- FDA, Pfizer bolster instructions for providers and recipients
This article is for subscribers only.
Moderna Inc.’s Covid-19 vaccine won backing from a panel of experts who advise U.S. regulators, setting the stage for its shot to be the second vaccine cleared in the U.S.
Food and Drug Administration advisers voted 20 to 0, with one abstention, on Thursday that the benefits of the vaccine outweigh any risk, giving a boost to efforts to ramp up the U.S. immunization campaign. The effort is initially focusing on health-care workers and seniors who live in long-term care facilities. The FDA could authorize the shot within the next day.